Prognostic impact of switching to the 2021 chronic kidney disease epidemiology collaboration creatinine-based equation in Caucasian patients with type 2 diabetes: the Renal Insufficiency and Cardiovascular events (RIACE) Italian Multicenter Study.
Humans
Male
Italy
/ epidemiology
Diabetes Mellitus, Type 2
/ diagnosis
Female
Renal Insufficiency, Chronic
/ diagnosis
Middle Aged
Aged
Glomerular Filtration Rate
Risk Assessment
Prognosis
Prospective Studies
Biomarkers
/ blood
Predictive Value of Tests
Cardiovascular Diseases
/ diagnosis
White People
Diabetic Nephropathies
/ diagnosis
Creatinine
/ blood
Kidney
/ physiopathology
Time Factors
Models, Biological
Risk Factors
Decision Support Techniques
Race Factors
All-cause mortality
Chronic kidney disease epidemiology collaboration equation
Estimated glomerular filtration rate
Race
Type 2 diabetes
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
24 Oct 2024
24 Oct 2024
Historique:
received:
31
07
2024
accepted:
19
09
2024
medline:
25
10
2024
pubmed:
25
10
2024
entrez:
25
10
2024
Statut:
epublish
Résumé
A Chronic Kidney Disease (CKD) Epidemiology Collaboration (EPI) formula not including a Black race coefficient has been recently developed and is now recommended in the US. The new (2021) equation was shown to yield higher estimated glomerular filtration rate (eGFR) values than the old (2009) one in a non-Black general population sample, thus reclassifying a significant number of individuals to a better eGFR category. However, reclassified individuals were previously shown to have a lower risk of progression to end-stage kidney disease, but higher adjusted risks for all-cause death and morbidity and mortality from cardiovascular disease than those not reclassified. This study evaluated the prognostic impact of switching from the 2009 to the 2021 CKD-EPI equation in non-Black individuals with type 2 diabetes. The Renal Insufficiency And Cardiovascular Events (RIACE) was a prospective cohort study enrolling 15,773 Caucasian patients in 19 Italian centers in 2006-2008. Cardiometabolic risk profile, treatments, complications, and comorbidities were assessed at baseline and eGFR was calculated with the two equations. Vital status was retrieved on 31 October 2015 for 15,656 participants (99.3%). With the 2021 equation, the eGFR value increased in all patients, except for 293 individuals with a 2009 eGFR ≥ 105 ml·min Changing from the 2009 to the 2021 CKD-EPI equation results in higher eGFR and lower CKD prevalence, with a lower risk of death in reclassified patients with an eGFR < 30 ml·min ClinicalTrials.gov, NCT00715481, retrospectively registered 15 July, 2008.
Sections du résumé
BACKGROUND
BACKGROUND
A Chronic Kidney Disease (CKD) Epidemiology Collaboration (EPI) formula not including a Black race coefficient has been recently developed and is now recommended in the US. The new (2021) equation was shown to yield higher estimated glomerular filtration rate (eGFR) values than the old (2009) one in a non-Black general population sample, thus reclassifying a significant number of individuals to a better eGFR category. However, reclassified individuals were previously shown to have a lower risk of progression to end-stage kidney disease, but higher adjusted risks for all-cause death and morbidity and mortality from cardiovascular disease than those not reclassified. This study evaluated the prognostic impact of switching from the 2009 to the 2021 CKD-EPI equation in non-Black individuals with type 2 diabetes.
METHODS
METHODS
The Renal Insufficiency And Cardiovascular Events (RIACE) was a prospective cohort study enrolling 15,773 Caucasian patients in 19 Italian centers in 2006-2008. Cardiometabolic risk profile, treatments, complications, and comorbidities were assessed at baseline and eGFR was calculated with the two equations. Vital status was retrieved on 31 October 2015 for 15,656 participants (99.3%).
RESULTS
RESULTS
With the 2021 equation, the eGFR value increased in all patients, except for 293 individuals with a 2009 eGFR ≥ 105 ml·min
CONCLUSION
CONCLUSIONS
Changing from the 2009 to the 2021 CKD-EPI equation results in higher eGFR and lower CKD prevalence, with a lower risk of death in reclassified patients with an eGFR < 30 ml·min
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov, NCT00715481, retrospectively registered 15 July, 2008.
Identifiants
pubmed: 39449120
doi: 10.1186/s12933-024-02450-5
pii: 10.1186/s12933-024-02450-5
doi:
Substances chimiques
Biomarkers
0
Creatinine
AYI8EX34EU
Banques de données
ClinicalTrials.gov
['NCT00715481']
Types de publication
Journal Article
Multicenter Study
Observational Study
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
377Informations de copyright
© 2024. The Author(s).
Références
Levey AS, Grams ME, Inker LA. Uses of GFR and albuminuria level in acute and chronic kidney disease. N Engl J Med. 2022;386:2120–8.
doi: 10.1056/NEJMra2201153
pubmed: 35648704
Warwick J, Holness J. Measurement of glomerular filtration rate. Semin Nucl Med. 2022;52:453–66.
doi: 10.1053/j.semnuclmed.2021.12.005
pubmed: 35063168
Traynor J, Mactier R, Geddes CC, Fox JG. How to measure renal function in clinical practice. BMJ. 2006;333:733–7.
doi: 10.1136/bmj.38975.390370.7C
pubmed: 17023465
pmcid: 1592388
Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function–measured and estimated glomerular filtration rate. N Engl J Med. 2006;354:2473–83.
doi: 10.1056/NEJMra054415
pubmed: 16760447
Florkowski CM, Chew-Harris JS. Methods of estimating GFR—different equations including CKD-EPI. Clin Biochem Rev. 2011;32:75–9.
pubmed: 21611080
pmcid: 3100284
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150.
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.
doi: 10.7326/0003-4819-150-9-200905050-00006
pubmed: 19414839
pmcid: 2763564
Williams P. Retaining race in chronic kidney disease diagnosis and treatment. Cureus. 2023;15:e45054.
pubmed: 37701164
pmcid: 10495104
Delgado C, Baweja M, Burrows NR, Crews DC, Eneanya ND, Gadegbeku CA, et al. Reassessing the inclusion of race in diagnosing kidney diseases: an interim report from the NKF-ASN Task Force. J Am Soc Nephrol. 2021;32:1305–17.
doi: 10.1681/ASN.2021010039
pubmed: 33837122
pmcid: 8259639
Sehgal AR. Race and the false Precision of glomerular filtration rate estimates. Ann Intern Med. 2020;173:1008–9.
doi: 10.7326/M20-4951
pubmed: 32805131
Gopalakrishnan C, Patorno E. Time to end the misuse of race in medicine: cases from nephrology. BMJ. 2021;375:n2435.
doi: 10.1136/bmj.n2435
pubmed: 34667058
Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med. 2021;385:1737–49.
doi: 10.1056/NEJMoa2102953
pubmed: 34554658
pmcid: 8822996
Delgado C, Baweja M, Crews DC, Eneanya ND, Gadegbeku CA, Inker LA, et al. A unifying approach for GFR estimation: recommendations of the NKF-ASN task force on reassessing the inclusion of race in diagnosing kidney disease. Am J Kidney Dis. 2022;79:268–e2881.
doi: 10.1053/j.ajkd.2021.08.003
pubmed: 34563581
Gama RM, Kalyesubula R, Fabian J, Mahalingasivam V. NICE takes ethnicity out of estimating kidney function. BMJ. 2021;374:n2159.
doi: 10.1136/bmj.n2159
pubmed: 34507980
Eurostat. Migration and migrant population statistics. Available online at https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Migration_and_migrant_population_statistics (accessed July 13, 2024).
Fu EL, Coresh J, Grams ME, Clase CM, Elinder CG, Paik J, et al. Removing race from the CKD-EPI equation and its impact on prognosis in a predominantly white European population. Nephrol Dial Transpl. 2023;38:119–28.
doi: 10.1093/ndt/gfac197
Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, et al. Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. J Hypertens. 2011;29:1802–9.
doi: 10.1097/HJH.0b013e3283495cd6
pubmed: 21738053
Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, et al. Gender differences in cardiovascular disease risk factors, treatments and complications in patients with type 2 diabetes: the RIACE Italian multicentre study. J Intern Med. 2013;274:176–91.
doi: 10.1111/joim.12073
pubmed: 23565931
Pugliese G, Solini A, Fondelli C, Trevisan R, Vedovato M, Nicolucci A, et al. Reproducibility of albuminuria in type 2 diabetic subjects. Findings from the Renal Insufficiency and Cardiovascular events (RIACE) study. Nephrol Dial Transpl. 2011;26:3950–4.
doi: 10.1093/ndt/gfr140
Penno G, Solini A, Orsi E, Bonora E, Fondelli C, Trevisan R, et al. Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 diabetes: the Renal Insufficiency and Cardiovascular events (RIACE) Italian multicentre study. Diabetologia. 2018;61:2277–89.
doi: 10.1007/s00125-018-4691-2
pubmed: 30032426
Orsi E, Solini A, Bonora E, Vitale M, Garofolo M, Fondelli C, et al. Retinopathy as an independent predictor of all-cause mortality in individuals with type 2 diabetes. Diabetes Metab. 2023;49:101413.
doi: 10.1016/j.diabet.2022.101413
pubmed: 36460217
Solini A, Penno G, Bonora E, Fondelli C, Orsi E, Arosio M, et al. Diverging association of reduced glomerular filtration rate and albuminuria with coronary and noncoronary events in patients with type 2 diabetes: the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. Diabetes Care. 2012;35:143–9.
doi: 10.2337/dc11-1380
pubmed: 22124714
Orsi E, Solini A, Bonora E, Fondelli C, Trevisan R, Vedovato M, et al. Haemoglobin A1c variability is a strong, independent predictor of all-cause mortality in patients with type 2 diabetes. Diabetes Obes Metab. 2018;20:1885–93.
doi: 10.1111/dom.13306
pubmed: 29582548
Koutsoyiannis D. Replacing histogram with smooth empirical probability density function estimated by K-moments. Sci. 2022;4:50.
doi: 10.3390/sci4040050
Penno G, Solini A, Bonora E, Orsi E, Fondelli C, Zerbini G, et al. Defining the contribution of chronic kidney disease to all-cause mortality in patients with type 2 diabetes: the Renal Insufficiency and Cardiovascular events (RIACE) Italian Multicenter Study. Acta Diabetol. 2018;55:603–12.
doi: 10.1007/s00592-018-1133-z
pubmed: 29574497
Atiquzzaman M, Er L, Djurdjev O, Bevilacqua M, Elliott M, Birks PC, et al. Implications of implementing the 2021 CKD-EPI equation without race on managing patients with kidney disease in British Columbia, Canada. Kidney Int Rep. 2024;9:830–42.
doi: 10.1016/j.ekir.2024.01.039
pubmed: 38765563
pmcid: 11101769
Farah RI, Alhajahjeh A, Al-Farahid O, Abuzaid H, Hiasat D, Rayyan R, et al. Comparison and evaluation of the 2009 and 2021 chronic kidney disease-epidemiological collaboration equations among Jordanian patients with type 2 diabetes mellitus. Acta Diabetol. 2024;61:169–80.
doi: 10.1007/s00592-023-02191-z
pubmed: 37805971
Vestergaard SV, Heide-Jørgensen U, Birn H, Christiansen CF. Effect of the refitted race-free eGFR formula on the CKD prevalence and mortality in the Danish Population. Clin J Am Soc Nephrol. 2022;17:426–8.
doi: 10.2215/CJN.14491121
pubmed: 35017201
pmcid: 8975036
Ferraro PM, Lombardi G, Gambaro G. Impact of the new, race-free CKD-EPI equation on prevalence and clinical outcomes of CKD in northeastern Italy: the INCIPE study. J Nephrol. 2022;35:1767–9.
doi: 10.1007/s40620-022-01284-2
pubmed: 35175579
Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJ, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380:1662–73.
doi: 10.1016/S0140-6736(12)61350-6
pubmed: 23013602
pmcid: 3771350
Matsushita K, Coresh J, Sang Y, Chalmers J, Fox C, Guallar E, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015;3:514–25.
doi: 10.1016/S2213-8587(15)00040-6
pubmed: 26028594
pmcid: 4594193
van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79:1341–52.
doi: 10.1038/ki.2010.536
pubmed: 21307840
Gansevoort RT, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int. 2011;80:93–104.
doi: 10.1038/ki.2010.531
pubmed: 21289597
pmcid: 3959732
Riley DR, Essa H, Austin P, Preston F, Kargbo I, Ibarburu GH, et al. All-cause mortality and cardiovascular outcomes with sodium-glucose co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes. Diabetes Obes Metab. 2023;25:2897–909.
doi: 10.1111/dom.15185
pubmed: 37385958